EHA: Johnson & Johnson's Darzalex branches out beyond myeloma with AL amyloidosis win

Blood disease Light Chain (AL) Amyloidosis currently has no FDA-approved therapies, but Johnson & Johnson is making its case for Darzalex to become the first.

Adding the recently approved subcutaneous version of the drug—known as Darzalex Faspro—to a trio of chemo drug cyclophosphamide, Takeda’s Velcade, and steroid dexamethasone cleared disease from the blood in 53% of newly diagnosed AL amyloidosis patients in a phase 3 trial, J&J said Saturday at the European Hematology Association’s virtual annual congress.